Tafasitamab

• A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/… Pending
  2024-518275-64-00 Phase II 1 country Instytut Hematologii I Transfuzjologii
• A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Parsacl… Recruiting
  2022-501687-18-00 Phase II 8 countries Incyte Corp.
• Phase 2a Study of Tafasitamab in Adults With Primary Autoimmune Blood Cell Disorders Recruiting
  2025-521286-27-00 Phase II/III 4 countries Incyte Corp.
• Response-adaptive to Epcoritamab In FIrst Relapse: A Phase II, response-adaptive, Open-Label, Multicenter Study to Evaluate the Efficacy of … Recruiting
  2024-514440-86-00 Phase II 1 country Fundacion Geltamo
• Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1… Recruiting
  2023-508196-36-00 Phase II 5 countries Karolinska University Hospital
• A Prospective Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (MOR00208) in Pediatr… Recruiting
  2024-511336-28-00 Phase I/II 1 country Universitaetsklinikum Tuebingen AöR
• A continued study in patients with Hematologic Cancers previously treated with Tafasitamab. Recruiting
  2022-500765-27-00 Phase III 3 countries Incyte Corp.
• MTR² Ended
  2022-502790-42-00 Phase II 1 country University Of Cologne
• A Phase 3 study of Tafasitamab plus Lenalidomide in patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Ended
  2023-505579-53-00 Phase III 10 countries Incyte Corp.
• A Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide in Patients with … Ended
  2023-507993-42-00 Phase I/II 5 countries Incyte Corp.
• VERLEN - Phase II, Open-Label Study evaluating efficacy of Lenalidomide and Tafasitamab combination associated to Rituximab in frontline Dif… Ended
  2023-507286-25-00 Phase II 2 countries LYSARC
• Clinical study of acalabrutinib and tafasitamab in previously treated marginal zone lymphoma Ended
  2024-514122-23-00 Phase II 2 countries Association International Extranodal Lymphoma Study Group (IELSG)
• A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab, versus Lenalidomide plus Rituximab in patients With Relapsed/Refr… Ended
  2023-504684-16-00 Phase III 16 countries Incyte Corp.
• Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients… Ended
  2022-500237-92-00 Phase III 11 countries Incyte Corp.
• A phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients aggressive Lymphoma. Ended
  2024-514775-17-00 Phase II 1 country Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR

Showing 1–15 of 15 trials